The pursuit of market outperformance leads investors to the practice of hand-picking stocks. Skillful choices can be a catalyst for significant wealth enhancement.
The price of Intellia Therapeutics Inc (NASDAQ: NTLA) closed at $9.42 in the last session, down -2.89% from day before closing price of $9.7. In other words, the price has decreased by -$2.89 from its previous closing price. On the day, 2.57 million shares were traded. NTLA stock price reached its highest trading level at $9.55 during the session, while it also had its lowest trading level at $9.34.
Ratios:
We take a closer look at NTLA’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 6.21 and its Current Ratio is at 6.21. In the meantime, Its Debt-to-Equity ratio is 0.13 whereas as Long-Term Debt/Eq ratio is at 0.09.
On November 11, 2025, Evercore ISI Downgraded its rating to In-line which previously was Outperform but kept the price unchanged to $8. JP Morgan Downgraded its Neutral to Underweight on November 07, 2025, while the target price for the stock was maintained at $5.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Dec 11 ’25 when LEONARD JOHN M sold 88,146 shares for $9.49 per share. The transaction valued at 836,384 led to the insider holds 1,038,928 shares of the business.
LEONARD JOHN M bought 88,146 shares of NTLA for $822,402 on Dec 11 ’25. On Oct 01 ’25, another insider, Schultes Birgit C, who serves as the EVP, Chief Scientific Officer of the company, sold 31 shares for $17.38 each. As a result, the insider received 539 and left with 105,184 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, NTLA now has a Market Capitalization of 1091117952 and an Enterprise Value of 678039872. For the stock, the TTM Price-to-Sale (P/S) ratio is 18.97 while its Price-to-Book (P/B) ratio in mrq is 1.46. Its current Enterprise Value per Revenue stands at 11.786 whereas that against EBITDA is -1.446.
Stock Price History:
The Beta on a monthly basis for NTLA is 2.05, which has changed by -0.19966996 over the last 52 weeks, in comparison to a change of 0.13927746 over the same period for the S&P500. Over the past 52 weeks, NTLA has reached a high of $28.25, while it has fallen to a 52-week low of $5.90. The 50-Day Moving Average of the stock is -26.00%, while the 200-Day Moving Average is calculated to be -16.83%.
Shares Statistics:
According to the various share statistics, NTLA traded on average about 7.36M shares per day over the past 3-months and 3493300 shares per day over the past 10 days. A total of 115.79M shares are outstanding, with a floating share count of 110.12M. Insiders hold about 4.93% of the company’s shares, while institutions hold 86.29% stake in the company. Shares short for NTLA as of 1764288000 were 44572813 with a Short Ratio of 6.06, compared to 1761868800 on 39075621. Therefore, it implies a Short% of Shares Outstanding of 44572813 and a Short% of Float of 43.169999999999995.
Earnings Estimates
The dynamic stock of Intellia Therapeutics Inc (NTLA) is currently being evaluated by a team of 19.0 analysts, each contributing to its current rating.The consensus estimate for the next quarter is -$0.99, with high estimates of -$0.89 and low estimates of -$1.07.
Analysts are recommending an EPS of between -$3.8 and -$4.11 for the fiscal current year, implying an average EPS of -$3.97. EPS for the following year is -$3.59, with 21.0 analysts recommending between -$1.96 and -$4.41.
Revenue Estimates
A total of 23 analysts have provided revenue estimates for NTLA’s current fiscal year. The highest revenue estimate was $68.3M, while the lowest revenue estimate was $44.65M, resulting in an average revenue estimate of $56.92M. In the same quarter a year ago, actual revenue was $57.88M
